A standalone theme covering the development of ACT101, an antibody candidate for SFTS treatment, under a joint development agreement with Abcontek, followed by the discontinuation of nonclinical studies in cynomolgus monkeys and veterinary diagnostic reagent development, and a shift in strategy toward early out-licensing using the data obtained.